Biomerieux SA Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/9/2026)
| Balance Sheet | Total Assets | 5,574,700,000.00 | ROE | 73.58 % |
| Balance Sheet | Total Equity | 4,102,100,000.00 | ROA | 7.13 % |
| Cashflow | Capital Expenditures | -335,300,000.00 | P/FCF | 22.50 |
| Cashflow | Free Cash Flow | 453,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 788,300,000.00 | P/CF | 12.93 |
| Income | Earnings per Share (diluted) | 3.34 | Div. Yield | 1.05 % |
| Income | Net Income | 397,500,000.00 | P/E | 25.64 |
| Income | Shares Outstanding | 119,012,000.00 | P/B | 2.48 |
| Income | Total Revenue | 4,069,800,000.00 | P/S | 2.50 |
Ratios calculated on: 10/14/2026
Company Description
bioMérieux S.A. develops and produces in vitro diagnostic solutions for private and hospital laboratories for the diagnosis of infectious diseases. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.biomerieux.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more